AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31746962 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted increase in non-HDL-C levels
Number of subjects: 12460
Study 30707935 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlay mesh placement (anterior component separation)
Number of subjects: 120
Study 30707935 — intervention group
Group type: COMPARATOR
Intervention: Underlay mesh placement (posterior component separation)
Number of subjects: 120
Study 30707935 — intervention group
Group type: COMPARATOR
Intervention: HADM (human acellular dermis)
Number of subjects: 120
Study 30707935 — intervention group
Group type: COMPARATOR
Intervention: PADM (porcine acellular dermis)
Number of subjects: 120
Study 28651508 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 40
Study 28651508 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 25727403 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing (GPAP)
Number of subjects: 22
Study 25727403 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate air polishing (SBAP)
Number of subjects: 22
Study 25727403 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaling
Number of subjects: 22
Study 23715024 — intervention group
Group type: EXPERIMENTAL
Intervention: Double continuous epidural analgesia (CEA)
Number of subjects: 66
Study 23715024 — intervention group
Group type: EXPERIMENTAL
Intervention: Single continuous epidural analgesia (CEA)
Number of subjects: 66
Study 23715024 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA)
Number of subjects: 66
Study 21617983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day)
Number of subjects: 250
Study 21617983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day) + Tolterodine (2 mg/day)
Number of subjects: 250
Study 21617983 — intervention group
Group type: COMPARATOR
Intervention: Control group (Tamsulosin alone)
Number of subjects: 250
Study 19222922 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tenofovir tablet formulation
Number of subjects: 43
Study 22276820 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and cyclophosphamide followed by docetaxel plus bevacizumab
Number of subjects: 1948
Study 22276820 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin and cyclophosphamide followed by docetaxel
Number of subjects: 1948
Study 15796639 — intervention group
Group type: EXPERIMENTAL
Intervention: URICA scale
Number of subjects: 234
Study 15796639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analyses
Number of subjects: 234
Study 15796639 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous measure of readiness to change
Number of subjects: 234
Study 12534446 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost administered for 5 days in SSc patients
Number of subjects: 40
Study 12534446 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost administered for 21 days in PAD patients
Number of subjects: 40
Study 9842825 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM) or sufentanil (ES) combined with bupivacaine
Number of subjects: 90
Study 9842825 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (IM) at fixed intervals
Number of subjects: 90
Study 9842825 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil and morphine combined with bupivacaine
Number of subjects: 90
Study 9842825 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sufentanil (IV)
Number of subjects: 90
Study 8017740 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enoxaparin once daily
Number of subjects: 572
Study 8017740 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin once daily
Number of subjects: 572
Study 8017740 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg enoxaparin every 12 hours
Number of subjects: 572
Study 2679036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 250
Study 2679036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 1278069 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 1593
Study 1278069 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies suggested include maximisation of efforts to enlist subject cooperation, management by family doctor or health centre, flexible appointment scheduling, and minimisation of doctors' ambivalence about treatment effectiveness.
Number of subjects: 1593
Study 1278069 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternatives such as low salt diets are suggested for further research due to the inevitability of some subjects rejecting long-term drug treatment.
Number of subjects: 1593
Study 31512067 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator-led, curriculum-driven small-group behavioral intervention
Number of subjects: 1000
Study 31512067 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (no intervention)
Number of subjects: 1000
Study 30149414 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise program over six weeks
Number of subjects: 28
Study 30149414 — intervention group
Group type: COMPARATOR
Intervention: Massage therapy (control)
Number of subjects: 28
Study 30149414 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise program
Number of subjects: 28
Study 27471836 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine artery occlusion in combination with laparoscopic myomectomy (LUAO+LM)
Number of subjects: 618
Study 27471836 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myomectomy (LM) alone
Number of subjects: 618
Study 24736093 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling device
Number of subjects: 30130
Study 24736093 — intervention group
Group type: COMPARATOR
Intervention: Regular cervical screening
Number of subjects: 30130
Study 24736093 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling device
Number of subjects: 30130
Study 22101054 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt containing B. animalis subsp. lactis Bb‐12 and inulin
Number of subjects: 46
Study 22101054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 22101054 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt
Number of subjects: 46
Study 20736784 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Disease Management Program (DMP), n = 86
Number of subjects: 173
Study 20736784 — intervention group
Group type: COMPARATOR
Intervention: Usual care, n = 87
Number of subjects: 173
Study 18786762 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exposure (GX)
Number of subjects: 108
Study 18786762 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-Based Classification (TBC)
Number of subjects: 108
Study 18786762 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Activity (GA)
Number of subjects: 108
Study 15824161 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/wk oral oltipraz
Number of subjects: 77
Study 15824161 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/wk oral oltipraz
Number of subjects: 77
Study 15824161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 12451428 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 ml) with diltiazem (120 mg)
Number of subjects: 10
Study 12451428 — intervention group
Group type: COMPARATOR
Intervention: Water with diltiazem (120 mg)
Number of subjects: 10
Study 10511903 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for initial treatment of bacterial complications of acute respiratory tract viral infections
Number of subjects: 0
Study 10511903 — intervention group
Group type: COMPARATOR
Intervention: Unjustified use of antibiotics
Number of subjects: 0
Study 7713831 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin administration (100 mg at 0800)
Number of subjects: 2
Study 2288898 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dry skin prick test
Number of subjects: 0
Study 2288898 — intervention group
Group type: COMPARATOR
Intervention: Control prick test
Number of subjects: 0
Study 6106149 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 7
Study 6106149 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 7
Study 6106149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30172595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5-3 mg/d
Number of subjects: 273
Study 30172595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 4.5-6 mg/d
Number of subjects: 273
Study 30172595 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/d
Number of subjects: 273
Study 30172595 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 10 mg/d
Number of subjects: 273
Study 28402521 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery-assisted en-masse retraction
Number of subjects: 31
Study 28402521 — intervention group
Group type: COMPARATOR
Intervention: Conventional en-masse retraction (Control)
Number of subjects: 31
Study 26696199 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite subcutaneous immunotherapy (SCIT) for 3 years
Number of subjects: 102
Study 26696199 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapy (ST)
Number of subjects: 102
Study 23332481 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral health music therapy intervention
Number of subjects: 16
Study 21865716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal submucosal administration of α‐GalCer‐pulsed DCs
Number of subjects: 0
Study 21865716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of activated NKT cells and submucosal injection of α‐GalCer‐pulsed DCs
Number of subjects: 0
Study 19302563 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate diet (Group A)
Number of subjects: 20
Study 19302563 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet (Group M)
Number of subjects: 20
Study 17503545 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group reminiscence therapy (8 sessions, 1 session per week)
Number of subjects: 102
Study 17503545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 102
Study 12619168 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention (12 weeks, twice per week for first month, weekly for second and third months)
Number of subjects: 38
Study 12619168 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 12619168 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 38
Study 12619168 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 10728945 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide regimens during intervention
Number of subjects: 4010
Study 10728945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4010
Study 9188113 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms.kg‐1 ondansetron
Number of subjects: 240
Study 9188113 — intervention group
Group type: COMPARATOR
Intervention: 50 micrograms.kg‐1 ondansetron
Number of subjects: 240
Study 1540344 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinflation using a new device
Number of subjects: 100
Study 1540344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 3886708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 10
Study 3886708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 10
Study 3886708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 10
Study 3886708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg
Number of subjects: 10
Study 3886708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (all doses)
Number of subjects: 10
Study 30293410 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple written material encouraging the benefits of physical activity (N=235)
Number of subjects: 546
Study 30293410 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=311)
Number of subjects: 546
Study 30132389 — intervention group
Group type: COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS) with anode over left dlPFC and cathode over right supraorbital region, 10 sessions of 20 minutes each.
Number of subjects: 18
Study 30132389 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study 30132389 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 18
Study 26386560 — intervention group
Group type: COMPARATOR
Intervention: 5-FU (800 mg/m²/day, days 1-5, every 4 weeks)
Number of subjects: 100
Study 26386560 — intervention group
Group type: EXPERIMENTAL
Intervention: wPTX (80 mg/m² on days 1, 8, and 15, every 4 weeks)
Number of subjects: 100
Study 23982995 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 2.5 mg
Number of subjects: 731
Study 23982995 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 1 mg
Number of subjects: 731
Study 23982995 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 5 mg
Number of subjects: 731
Study 22938031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding lag screw
Number of subjects: 80
Study 22938031 — intervention group
Group type: COMPARATOR
Intervention: Non-sliding lag screw
Number of subjects: 80
Study 20478939 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic aspiration (SPA)
Number of subjects: 48
Study 20478939 — intervention group
Group type: COMPARATOR
Intervention: Urine catheterization (UC)
Number of subjects: 48
Study 18829908 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg-stance radiographs (alternating right and left)
Number of subjects: 45
Study 15753902 — intervention group
Group type: EXPERIMENTAL
Intervention: mUV/VIS phototherapy (UV‐B 5%, UV‐A 25%, visible light 70%)
Number of subjects: 49
Study 15753902 — intervention group
Group type: EXPERIMENTAL
Intervention: mUV/VIS phototherapy
Number of subjects: 49
Study 15753902 — intervention group
Group type: COMPARATOR
Intervention: low‐intensity visible light (control)
Number of subjects: 49
Study 12324673 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme (SMP)
Number of subjects: 280
Study 9806261 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyle starch solution (HES)
Number of subjects: 101
Study 9806261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9% solution)
Number of subjects: 101
Study 7632455 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual advice plus individual relapse prevention counseling
Number of subjects: 175
Study 7632455 — intervention group
Group type: COMPARATOR
Intervention: Usual advice from obstetrician or nurse midwife
Number of subjects: 175
Study 2781235 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 1.2 g/day orally for 6 months
Number of subjects: 16
Study 2781235 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study 359018 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (200-600 mg twice daily)
Number of subjects: 11
Study 359018 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (once daily at optimum dose)
Number of subjects: 11
Study 359018 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (once daily)
Number of subjects: 11
Study 359018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 359018 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 11
Study 30488510 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination (3 doses)
Number of subjects: 117073
Study 30488510 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination (with additional information)
Number of subjects: 117073
Study 30488510 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination (adhering to recommended intervals)
Number of subjects: 117073
Study 29683334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) and posterior bite block (BB)
Number of subjects: 16
Study 29683334 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 16
Study 26678511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS)
Number of subjects: 0
Study 24420499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight computerized glucose control (TGC)
Number of subjects: 2684
Study 24420499 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose control (CGC)
Number of subjects: 2684
Study 22828155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and propofol (group T2)
Number of subjects: 80
Study 22828155 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (group T1)
Number of subjects: 80
Study 22828155 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (group S1)
Number of subjects: 80
Study 22828155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and propofol (group S2)
Number of subjects: 80
Study 20331572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation counseling during medical care
Number of subjects: 237
Study 18200389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectic‐didactic method therapy (40 sessions) for research group (RG)
Number of subjects: 8
Study 18200389 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (CG1)
Number of subjects: 8
Study 18200389 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (CG2) - children with normal development (ND)
Number of subjects: 8
Study 16025017 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced digital fluoroscopic video (DFV) combined with distortion compensated roentgen analysis (DCRA)
Number of subjects: 20
Study 11157185 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily for 14 days
Number of subjects: 24
Study 11157185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11367725 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 350
Study 11367725 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 350
Study 8106965 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet therapy
Number of subjects: 0
Study 2557764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal lavage followed by scrape‐Cytobrush
Number of subjects: 74
Study 2557764 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrape‐Cytobrush followed by cervicovaginal lavage
Number of subjects: 74
Study 2557764 — intervention group
Group type: COMPARATOR
Intervention: Scrape‐Cytobrush
Number of subjects: 74
Study 2557764 — intervention group
Group type: COMPARATOR
Intervention: Cervicovaginal lavage
Number of subjects: 74
Study 8044721 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 2.5 mg
Number of subjects: 130
Study 8044721 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 5 mg
Number of subjects: 130
Study 8044721 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130
Study 666950 — intervention group
Group type: EXPERIMENTAL
Intervention: Medigoxin
Number of subjects: 5
Study 666950 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 5
Study 31970430 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) TKA
Number of subjects: 34
Study 31970430 — intervention group
Group type: COMPARATOR
Intervention: Anterior-stabilized (AS) TKA
Number of subjects: 34
Study 31383027 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative management (open reduction and internal fixation - ORIF)
Number of subjects: 70
Study 31383027 — intervention group
Group type: COMPARATOR
Intervention: Non-operative management (humeral brace until fracture union)
Number of subjects: 70
Study 31383027 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative management (ORIF)
Number of subjects: 70
Study 31383027 — intervention group
Group type: COMPARATOR
Intervention: Non-operative management (humeral brace)
Number of subjects: 70
Study 28333301 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol ≥200 mg/dl
Number of subjects: 1228
Study 28333301 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal lipoprotein levels
Number of subjects: 1228
Study 28333301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-C <50 mg/dl
Number of subjects: 1228
Study 28333301 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated triglycerides ≥150 mg/dl
Number of subjects: 1228
Study 28333301 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated LDL-C ≥130 mg/dl
Number of subjects: 1228
Study 28333301 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated total cholesterol
Number of subjects: 1228
Study 28333301 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated LDL-C
Number of subjects: 1228
Study 28333301 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated triglycerides
Number of subjects: 1228
Study 28333301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-C
Number of subjects: 1228
Study 26655958 — intervention group
Group type: EXPERIMENTAL
Intervention: GBAT
Number of subjects: 35
Study 26655958 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 35
Study 25113095 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (30 × 0.5 mg)
Number of subjects: 9
Study 22296762 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS messaging intervention (n=8)
Number of subjects: 21
Study 22296762 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=13)
Number of subjects: 21
Study 22296762 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting pills method (Intervention group)
Number of subjects: 21
Study 22296762 — intervention group
Group type: COMPARATOR
Intervention: Counting pills method (Control group)
Number of subjects: 21
Study 22296762 — intervention group
Group type: EXPERIMENTAL
Intervention: Microelectronic monitoring (Intervention group)
Number of subjects: 21
Study 22296762 — intervention group
Group type: COMPARATOR
Intervention: Microelectronic monitoring (Control group)
Number of subjects: 21